Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYSCRAPER-09: Atezolizumab + Tiragolumab in 1L SCCHN
NCT04665843Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Atezolizumab + Tiragolumab with Atezolizumab + Placebo (2 arms). Primary endpoint: Objective Response Rate at 30.6 months. Started Mar 2021; status: completed.
02
Drugs
tiragolumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04665843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665843.